Chimeric antigen receptors (CAR) are engineered fusion proteins designed to target T cells
to antigens expressed on cancer cells. CAR T cells are now an established treatment for …

The remarkable clinical activity of chimeric antigen receptor (CAR) therapies in B cell and
plasma cell malignancies has validated the use of this therapeutic class for liquid cancers …

Background Immunotherapy with chimeric antigen receptor (CAR)–expressing T cells that
target the disialoganglioside GD2 expressed on tumor cells may be a therapeutic option for …

Adoptive cell therapies (ACTs) have existed for decades. From the initial infusion of tumor-
infiltrating lymphocytes to the subsequent specific enhanced T cell receptor (TCR)-T and …

Vα24-invariant natural killer T cells (NKTs) have anti-tumor properties that can be enhanced
by chimeric antigen receptors (CARs). Here we report updated interim results from the first-in …

T cells can acquire a broad spectrum of differentiation states following activation. At the
extreme ends of this continuum are short-lived cells equipped with effector machinery and …

Despite impressive progress, more than 50% of patients treated with CD19-targeting
chimeric antigen receptor T cells (CAR19) experience progressive disease. Ten of 16 …

Abstract Chimeric Antigen Receptor (CAR) T-cells represent a breakthrough in personalized
cancer therapy. In this strategy, synthetic receptors comprised of antigen recognition …

Several non-redundant features of the tumour microenvironment facilitate
immunosuppression and limit anticancer immune responses. These include physical …

Autologous chimeric antigen receptor (CAR) T cells have changed the therapeutic
landscape in haematological malignancies. Nevertheless, the use of allogeneic CAR T cells …